The Cabrini Precision Oncology Program aims to redefine models of cancer care in Victoria. Through genomic profiling, treatment will be personalised to the specific needs of each patient, connecting them to effective advanced therapies.

Despite significant progress, cancer treatment remains amongst the least effective of all chronic diseases. Supported by the PMF Foundation, Cabrini Health and Monash University will partner to address this generational challenge, expanding access to genomic profiling for cancer patients across South-East Victoria.

Led by Professor Gary Richardson OAM, the program will identify key molecular features of each patient’s cancer and select suitable therapies, including clinical trials. This personalised approach creates new possibilities for those with rare and aggressive cancers, often underserved by current models of care.

The program will also ensure equitable access by lowering the barriers to precision oncology for both public and private sector patients. This will be made possible through a strategic partnership that leverages the clinical and academic excellence of both Cabrini Health and Monash University.

For Professor Richardson, “the PMF Foundation has allowed us to have up to 1,000 more Victorians undergoing genomic profiling within five years and enter clinical trials that they would not otherwise have had access to.”

Through the program, researchers from Cabrini Heath and Monash University will collaborate to conduct genomics-led cancer research, integrating preclinical models and clinical datasets from both organisations. Together, translational pathways towards new therapies will be pursued, identifying and meeting the evolving needs of future patient populations.